Antibody drug conjugates (ADCs) having enzymatically cleavable groups
The invention relates to novel binder-drug conjugates (ADCs) having improved properties, to active metabolites of these ADCs and to processes for their preparation. The present invention furthermore relates to the use of these conjugates for the treatment and/or prevention of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases.
1. An antibody-drug conjugate of formula (I):
or a pharmaceutically acceptable salt thereof,
wherein:
AK is an antibody or an antigen-binding antibody fragment thereof;
n is a number from 1 to 50;
X 1 is N,
X 2 is N and
X 3 is C;
or
X 1 is N,
X 2 is C and
X 3 is N;
or
X 1 is CH or CF,
X 2 is C and
X 3 is N;
or
X 1 is NH,
X 2 is C and
X 3 is C;
or
X 1 is CH,
X 2 is N and
X 3 is C;
R 1 is methyl;
R 2 is methyl, ethyl, —CH 2 —CH(CH 3 ) 2 , —CH 2 —C(═O)OH or isopropyl;
R 3 is methyl, ethyl, —CH 2 —CH(CH 3 ) 2 or —CH 2 —C(═O)—NH 2 ; and
M is the group
#—C(═O)—CH(CH 3 )—NH—C(═O)—CH 2 —NH—C(═O)—CH 2 —CH(##)-COOH,
#—C(═O)—CH(CH 3 )—NH—C(═O)—CH 2 —NH—C(═O)—CH(##)—CH 2 —COOH,
#—C(═O)—CH(CH 3 )—NH—C(═O)—CH 2 —W,
#—C(═O)—CH 2 —NH—C(═O)—CH 2 —CH(##)-COOH,
#—C(═O)—CH 2 —NH—C(═O)—CH(##)—CH 2 —COOH,
#—C(═O)—CH 2 —W,
#—C(═O)—CH(CH 3 )—NH—C(═O)—(CH 2 ) 2-8 —C(═O)-###,
#—C(═O)—(CH 2 ) 3 —C(═O)-###,
#—C(═O)—CH(CH 3 )—NH—C(═O)—(CH 2 ) 5 —W,
#—C(═O)—CH(CH 3 )—NH—C(═O)—(CH 2 )-##, or
#—C(═O)—CH(CH 3 )—NH—C(═O)—(CH 2 —CH 2 —O) 1-8 —(CH 2 ) 2 —NH—C(═O)—CH 2 -##;
wherein:
# represents the bond to —NR 1 —,
W is the group:
## represents the bond to a sulfur atom of a cysteine side-chain of the antibody or antigen-binding antibody fragment thereof; and
### represents the bond to a nitrogen atom of a lysine side-chain of the antibody or antigen-binding antibody fragment thereof,
wherein the antibody or antigen-binding antibody fragment binds to CD123.
2. The antibody-drug conjugate of claim 1 , or a pharmaceutically acceptable salt thereof,
wherein:
X 1 is CH,
X 2 is C,
X 3 is N;
R 1 is methyl;
R 2 is methyl, —CH 2 —CH(CH 3 ) 2 , —CH 2 —C(═O)OH or isopropyl;
R 3 is methyl, —CH 2 —CH(CH 3 ) 2 or —CH 2 —C(═O)—NH 2 ; and
M is the group:
#—C(═O)—CH(CH 3 )—NH—C(═O)—CH 2 —NH—C(═O)—CH 2 —CH(##)-COOH,
#—C(═O)—CH(CH 3 )—NH—C(═O)—CH 2 —NH—C(═O)—CH(##)—CH 2 —COOH,
#—C(═O)—CH(CH 3 )—NH—C(═O)—CH 2 —W,
#—C(═O)—CH 2 —NH—C(═O)—CH 2 —CH(##)-COOH,
#—C(═O)—CH 2 —NH—C(═O)—CH(##)—CH 2 —COOH,
#—C(═O)—CH 2 —W,
#—C(═O)—CH(CH 3 )—NH—C(═O)—(CH 2 ) 3 —C(═O)-###,
#—C(═O)—(CH 2 ) 3 —C(═O)-###,
#—C(═O)—CH(CH 3 )—NH—C(═O)—(CH 2 ) 5 —W,
#—C(═O)—CH(CH 3 )—NH—C(═O)—(CH 2 )-##, or
#—C(═O)—CH(CH 3 )—NH—C(═O)—(CH 2 —CH 2 —O) 4 —(CH 2 ) 2 —NH—C(═O)—CH 2 -##.
3. The antibody-drug conjugate of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:
R 2 is methyl;
R 3 is methyl, —CH 2 —CH(CH 3 ) 2 , or —CH 2 —C(═O)—NH 2 ;
M is the group
#—C(═O)—CH(CH 3 )—NH—C(═O)—CH 2 —NH—C(═O)—CH 2 —CH(##)-COOH,
#—C(═O)—CH(CH 3 )—NH—C(═O)—CH 2 —NH—C(═O)—CH(##)—CH 2 —COOH,
#—C(═O)—CH(CH 3 )—NH—C(═O)—(CH 2 ) 3 —C(═O)-###;
#—C(═O)—CH(CH 3 )—NH—C(═O)—(CH 2 ) 5 —W,
#—C(═O)—CH(CH 3 )—NH—C(═O)—(CH 2 )-##, or
#—C(═O)—CH(CH 3 )—NH—C(═O)—(CH 2 —CH 2 —O) 4 —(CH 2 ) 2 —NH—C(═O)—CH 2 -##.
4. The antibody-drug conjugate of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:
R 2 is methyl;
R 3 is —CH 2 —C(═O)—NH 2 ;
M is the group:
#—C(═O)—CH(CH 3 )—NH—C(═O)—(CH 2 ) 3 —C(═O)-###; or
#—C(═O)—CH(CH 3 )—NH—C(═O)—(CH 2 ) 5 —W.
5. The antibody-drug conjugate of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:
n is a number from 1 to 20;
R 2 is methyl;
R 3 is —CH 2 —C(═O)—NH 2 ;
M is the group
#—C(═O)—CH(CH 3 )—NH—C(═O)—(CH 2 ) 3 —C(═O)-###.
6. The antibody-drug conjugate of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the antibody-drug conjugate has a structure selected from the group consisting of
wherein
AK1 is the antibody or antigen-binding fragment thereof, which is attached via a sulfur atom of a cysteine side-chain,
AK2 is the antibody or antigen-binding fragment thereof, which is attached via a nitrogen atom of a lysine side-chain, and
n is a number from 1 to 50.
7. The antibody-drug conjugate of claim 6 , or a pharmaceutically acceptable salt thereof, wherein n is a number from 1 to 20.
8. The antibody-drug conjugate of claim 7 , a pharmaceutically acceptable salt thereof, wherein n is a number from 1 to 8.
9. The antibody-drug conjugate of claim 8 , or a pharmaceutically acceptable salt thereof, wherein n is a number from 4 to 8.
10. The antibody-drug conjugate of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the antibody or the antigen-binding antibody fragment thereof, after binding to CD123, is internalized by the target cell through the binding.
11. A pharmaceutical composition comprising at least one antibody-drug conjugate of claim 1 , or a pharmaceutically acceptable salt thereof, in combination with an inert, non-toxic, pharmaceutically suitable auxiliary.
12. The antibody-drug conjugate of claim 1 , wherein the antibody or antigen-binding antibody fragment comprises a variable heavy chain comprising the variable CDR1 sequence of the heavy chain, as shown in SEQ ID NO: 82, the variable CDR2 sequence of the heavy chain, as shown in SEQ ID NO: 83, and the variable CDR3 sequence of the heavy chain, as shown in SEQ ID NO: 84; and a variable light chain comprising the variable CDR1 sequence of the light chain, as shown in SEQ ID NO: 86, the variable CDR2 sequence of the light chain, as shown in SEQ ID NO: 87, and the variable CDR3 sequence of the light chain, as shown in SEQ ID NO: 88.
13. The antibody-drug conjugate of claim 12 , wherein the variable heavy chain comprises SEQ ID NO: 81 and the variable light chain comprises SEQ ID NO: 85.
14. The antibody-drug conjugate of claim 12 , wherein the antibody or antigen-binding fragment comprises a heavy chain comprising SEQ ID NO: 89 and a light chain comprising SEQ ID NO: 90.
15. The antibody-drug conjugate of claim 6 , or a pharmaceutically acceptable salt thereof, wherein the antibody-drug conjugate has the structure:
16. The antibody-drug conjugate of claim 15 , wherein the antibody or antigen-binding antibody fragment comprises a variable heavy chain comprising the variable CDR1 sequence of the heavy chain, as shown in SEQ ID NO: 82, the variable CDR2 sequence of the heavy chain, as shown in SEQ ID NO: 83, and the variable CDR3 sequence of the heavy chain, as shown in SEQ ID NO: 84; and a variable light chain comprising the variable CDR1 sequence of the light chain, as shown in SEQ ID NO: 86, the variable CDR2 sequence of the light chain, as shown in SEQ ID NO: 87, and the variable CDR3 sequence of the light chain, as shown in SEQ ID NO: 88.
17. The antibody-drug conjugate of claim 16 , wherein the variable heavy chain comprises SEQ ID NO: 81 and the variable light chain comprises SEQ ID NO: 85.
18. The antibody-drug conjugate of claim 16 , wherein the antibody or antigen-binding fragment comprises a heavy chain comprising SEQ ID NO: 89 and a light chain comprising SEQ ID NO: 90.
19. The antibody-drug conjugate of claim 6 , or a pharmaceutically acceptable salt thereof, wherein the antibody-drug conjugate has the structure:
20. The antibody-drug conjugate of claim 19 , wherein the antibody or antigen-binding antibody fragment comprises a variable heavy chain comprising the variable CDR1 sequence of the heavy chain, as shown in SEQ ID NO: 82, the variable CDR2 sequence of the heavy chain, as shown in SEQ ID NO: 83, and the variable CDR3 sequence of the heavy chain, as shown in SEQ ID NO: 84; and a variable light chain comprising the variable CDR1 sequence of the light chain, as shown in SEQ ID NO: 86, the variable CDR2 sequence of the light chain, as shown in SEQ ID NO: 87, and the variable CDR3 sequence of the light chain, as shown in SEQ ID NO: 88.
21. The antibody-drug conjugate of claim 20 , wherein the variable heavy chain comprises SEQ ID NO: 81 and the variable light chain comprises SEQ ID NO: 85.
22. The antibody-drug conjugate of claim 20 , wherein the antibody or antigen-binding fragment comprises a heavy chain comprising SEQ ID NO: 89 and a light chain comprising SEQ ID NO: 90.
23. The antibody-drug conjugate of claim 6 , or a pharmaceutically acceptable salt thereof, wherein the antibody-drug conjugate has the structure:
24. The antibody-drug conjugate of claim 23 , wherein the antibody or antigen-binding antibody fragment comprises a variable heavy chain comprising the variable CDR1 sequence of the heavy chain, as shown in SEQ ID NO: 82, the variable CDR2 sequence of the heavy chain, as shown in SEQ ID NO: 83, and the variable CDR3 sequence of the heavy chain, as shown in SEQ ID NO: 84; and a variable light chain comprising the variable CDR1 sequence of the light chain, as shown in SEQ ID NO: 86, the variable CDR2 sequence of the light chain, as shown in SEQ ID NO: 87, and the variable CDR3 sequence of the light chain, as shown in SEQ ID NO: 88.
25. The antibody-drug conjugate of claim 24 , wherein the variable heavy chain comprises SEQ ID NO: 81 and the variable light chain comprises SEQ ID NO: 85.
26. The antibody-drug conjugate of claim 24 , wherein the antibody or antigen-binding fragment comprises a heavy chain comprising SEQ ID NO: 89 and a light chain comprising SEQ ID NO: 90.
27. The antibody-drug conjugate of claim 6 , or a pharmaceutically acceptable salt thereof, wherein the antibody-drug conjugate has the structure:
28. The antibody-drug conjugate of claim 27 , wherein the antibody or antigen-binding antibody fragment comprises a variable heavy chain comprising the variable CDR1 sequence of the heavy chain, as shown in SEQ ID NO: 82, the variable CDR2 sequence of the heavy chain, as shown in SEQ ID NO: 83, and the variable CDR3 sequence of the heavy chain, as shown in SEQ ID NO: 84; and a variable light chain comprising the variable CDR1 sequence of the light chain, as shown in SEQ ID NO: 86, the variable CDR2 sequence of the light chain, as shown in SEQ ID NO: 87, and the variable CDR3 sequence of the light chain, as shown in SEQ ID NO: 88.
29. The antibody-drug conjugate of claim 28 , wherein the variable heavy chain comprises SEQ ID NO: 81 and the variable light chain comprises SEQ ID NO: 85.
30. The antibody-drug conjugate of claim 28 , wherein the antibody or antigen-binding fragment comprises a heavy chain comprising SEQ ID NO: 89 and a light chain comprising SEQ ID NO: 90.
31. The antibody-drug conjugate of claim 6 , or a pharmaceutically acceptable salt thereof, wherein the antibody-drug conjugate has the structure:
32. The antibody-drug conjugate of claim 31 , wherein the antibody or antigen-binding antibody fragment comprises a variable heavy chain comprising the variable CDR1 sequence of the heavy chain, as shown in SEQ ID NO: 82, the variable CDR2 sequence of the heavy chain, as shown in SEQ ID NO: 83, and the variable CDR3 sequence of the heavy chain, as shown in SEQ ID NO: 84; and a variable light chain comprising the variable CDR1 sequence of the light chain, as shown in SEQ ID NO: 86, the variable CDR2 sequence of the light chain, as shown in SEQ ID NO: 87, and the variable CDR3 sequence of the light chain, as shown in SEQ ID NO: 88.
33. The antibody-drug conjugate of claim 32 , wherein the variable heavy chain comprises SEQ ID NO: 81 and the variable light chain comprises SEQ ID NO: 85.
34. The antibody-drug conjugate of claim 32 , wherein the antibody or antigen-binding fragment comprises a heavy chain comprising SEQ ID NO: 89 and a light chain comprising SEQ ID NO: 90.
35. The antibody-drug conjugate of claim 6 , or a pharmaceutically acceptable salt thereof, wherein the antibody-drug conjugate has the structure:
36. The antibody-drug conjugate of claim 35 , wherein the antibody or antigen-binding antibody fragment comprises a variable heavy chain comprising the variable CDR1 sequence of the heavy chain, as shown in SEQ ID NO: 82, the variable CDR2 sequence of the heavy chain, as shown in SEQ ID NO: 83, and the variable CDR3 sequence of the heavy chain, as shown in SEQ ID NO: 84; and a variable light chain comprising the variable CDR1 sequence of the light chain, as shown in SEQ ID NO: 86, the variable CDR2 sequence of the light chain, as shown in SEQ ID NO: 87, and the variable CDR3 sequence of the light chain, as shown in SEQ ID NO: 88.
37. The antibody-drug conjugate of claim 36 , wherein the variable heavy chain comprises SEQ ID NO: 81 and the variable light chain comprises SEQ ID NO: 85.
38. The antibody-drug conjugate of claim 36 , wherein the antibody or antigen-binding fragment comprises a heavy chain comprising SEQ ID NO: 89 and a light chain comprising SEQ ID NO: 90.
39. The antibody-drug conjugate of claim 6 , or a pharmaceutically acceptable salt thereof, wherein the antibody-drug conjugate has the structure:
40. The antibody-drug conjugate of claim 39 , wherein the antibody or antigen-binding antibody fragment comprises a variable heavy chain comprising the variable CDR1 sequence of the heavy chain, as shown in SEQ ID NO: 82, the variable CDR2 sequence of the heavy chain, as shown in SEQ ID NO: 83, and the variable CDR3 sequence of the heavy chain, as shown in SEQ ID NO: 84; and a variable light chain comprising the variable CDR1 sequence of the light chain, as shown in SEQ ID NO: 86, the variable CDR2 sequence of the light chain, as shown in SEQ ID NO: 87 , and the variable CDR 3 sequence of the light chain, as shown in SEQ ID NO: 88.
41. The antibody-drug conjugate of claim 40 , wherein the variable heavy chain comprises SEQ ID NO: 81 and the variable light chain comprises SEQ ID NO: 85.
42. The antibody-drug conjugate of claim 40 , wherein the antibody or antigen-binding fragment comprises a heavy chain comprising SEQ ID NO: 89 and a light chain comprising SEQ ID NO: 90.
43. A method for treatment of a disease associated with CD123 expression, comprising administering to a subject in need thereof an effective amount of the antibody-drug conjugate of claim 16 .
44. A method for treatment of a disease associated with CD123 expression, comprising administering to a subject in need thereof an effective amount of the antibody-drug conjugate of claim 20 .
45. A method for treatment of a disease associated with CD123 expression, comprising administering to a subject in need thereof an effective amount of the antibody-drug conjugate of claim 24 .
46. A method for treatment of a disease associated with CD123 expression, comprising administering to a subject in need thereof an effective amount of the antibody-drug conjugate of claim 28 .
47. A method for treatment of a disease associated with CD123 expression, comprising administering to a subject in need thereof an effective amount of the antibody-drug conjugate of claim 32 .
48. A method for treatment of a disease associated with CD123 expression, comprising administering to a subject in need thereof an effective amount of the antibody-drug conjugate of claim 36 .
49. A method for treatment of a disease associated with CD123 expression, comprising administering to a subject in need thereof an effective amount of the antibody-drug conjugate of claim 40 .
50. A method for treatment of a disease associated with CD123 expression, comprising administering to a subject in need thereof an effective amount of the antibody-drug conjugate of claim 1 .